Technology
Leading Innovator and Developer of Oral Cancer Early Detection Solutions
Our test and digital platform empower clinicians and improve potential outcomes by aiding in early detection of oral cancer which includes oral and oropharyngeal cancer.
Our test and digital platform empower clinicians and improve potential outcomes by aiding in early detection of oral cancer which includes oral and oropharyngeal cancer.
Vigilant Biosciences® product is based on advanced patented technology, including an innovative methodology for assessing multiple biomarkers that, together with other clinical factors, can aid clinicians in the early detection of oral cancer. The clinically validated† test contributes to early and accurate† detection of oral cancer, potentially even before visual or physical indicators.
Vigilant Biosciences® digital platform brings technology and early oral cancer detection testing together. The integrated management system assists clinicians in managing patient test data and reporting over time. Clinicians can now easily identify patients that may be high risk to have, or develop, oral cancer at the earliest possible time and refer these patients to a specialist for appropriate treatment.
Vigilant Biosciences® product is based on advanced patented technology, including an innovative methodology for assessing CD44, a tumor-initiating and stem cell-associated biomarker, and total protein levels that, together with other clinical factors, can aid clinicians in the early detection of oral cancer. The clinically validated† test contributes to early and accurate† detection of oral cancer, potentially even before visual or physical indicators.
This foundational science leverages nearly two decades of clinical research conducted by Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
Vigilant Biosciences® digital platform brings technology and early oral cancer detection testing together. The integrated management system assists clinicians in managing patient test data and reporting over time. Clinicians can now easily identify patients that may be high risk to have, or develop, oral cancer at the earliest possible time and refer these patients to a specialist for appropriate treatment.
†Clinical Data on File
†Clinical Data on File
© 2020 Vigilant Biosciences